A retrospective study of sentinel lymph node biopsy for skin cancer in Japan: Comparison with breast cancer and evaluation of factors related to its use
Cancer Medicine · 2023
DOI: 10.1002/cam4.6677 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Shogo Wada und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Melanoma, Breast Neoplasms, Skin Neoplasms, Carcinoma, Merkel Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Cancer Center Research and Development Fund.
Abstract (Originalsprache)
Background
Sentinel lymph node biopsy (SLNB) underuse has been reported for skin cancers; however, actual performance rates have not been compared. The objective of this study was to investigate the SLNB performance rate in skin cancers covered by health insurance in Japan and compare it with that in breast cancer.
Methods
This was a retrospective study of the SLNB performance rate in SLNB‐eligible patients with breast or skin cancer from 2018 to 2019, utilizing a database linked to the Hospital‐Based Cancer Registry and Diagnosis Procedure Combination survey. Demographic and tumor characteristics were analyzed using logistic regression.
Results
A total of 71,652 patients were included in this study. SLNB was performed in 86.4% (57,904/67,036) of the patients with breast cancer, 44.7% (694/1552) with melanomas, 3.1% (89/2849) with squamous cell carcinomas (SCCs), and 13.5% (29/215) with Merkel cell carcinomas (MCCs). The performance rate of SLNB was significantly lower for skin cancers than for breast cancers (odds ratio [OR], 0.03; p < 0.001). In addition, the performance rates of SLNB were significantly lower for SCCs and MCCs than for melanomas (SCC: OR, 0.04; p < 0.001; MCC: OR, 0.19; p < 0.001). Factors associated with SLNB performance included age, sex, year of incidence, primary tumor site, T stage, and number of hospital beds.
Conclusions
SLNB is underutilized for skin cancer. Further investigation is required to explore the reasons for its underutilization so that it may be implemented more universally.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Division of Health Services Research, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.
- Department of Public Health and Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
ORCID-Profile: Shogo Wada, Taisuke Ishii, Dai Ogata, Eiji Nakano, Kenjiro Namikawa, Naoya Yamazaki, Takahiro Higashi
Förderung
- The National Cancer Center Research and Development Fund
Zitieren
APA
Wada, S., Watanabe, T., Ishii, T., Ichinose, Y., Rikitake, R., Ogata, D., Nakano, E., Namikawa, K., Yamazaki, N., & Higashi, T. (2023). A retrospective study of sentinel lymph node biopsy for skin cancer in Japan: Comparison with breast cancer and evaluation of factors related to its use. Cancer Medicine. https://doi.org/10.1002/cam4.6677
Vancouver
Wada S, Watanabe T, Ishii T, Ichinose Y, Rikitake R, Ogata D, et al. A retrospective study of sentinel lymph node biopsy for skin cancer in Japan: Comparison with breast cancer and evaluation of factors related to its use. Cancer Medicine. 2023. doi:10.1002/cam4.6677
BibTeX
@article{Wada2023,
author = {Wada, Shogo and Watanabe, Tomone and Ishii, Taisuke and Ichinose, Yuichi and Rikitake, Ryoko and Ogata, Dai and Nakano, Eiji and Namikawa, Kenjiro and Yamazaki, Naoya and Higashi, Takahiro},
title = {A retrospective study of sentinel lymph node biopsy for skin cancer in Japan: Comparison with breast cancer and evaluation of factors related to its use},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6677}
}
EUVIMED